<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250312225205
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;v=2.18.0.post9+e462414&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20250312225205" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 13 Mar 2025 02:52:06 +0000</lastbuilddate>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072462/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO2. Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0103. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Excess body fat plays a pivotal role in the pathogenesis of heart failure with preserved ejection fraction (HFpEF). HU6 is a novel, controlled metabolic accelerator that enhances mitochondrial uncoupling resulting in increased metabolism and fat-specific weight loss.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To assess efficacy and safety of HU6 in reducing body weight, improving peak volume of oxygen consumption (VO2) and body composition among patients with obesity-related HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Exploratory Phase 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of HU6 for Subjects With Obese HFpEF (HuMAIN-HFpEF) trial was a multicenter, dose-escalation randomized clinical trial among patients with chronic stable HFpEF and obesity. Data were analyzed from July to October 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: HU6 treatment for 19 weeks, starting at 150 mg per day and potentially up titrated to 450 mg per day based on safety and tolerability vs placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was change in body weight.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 66 participants randomized (mean [SD] age, 64.5 [12] years; 38 female [58%]; mean [SD] weight, 110.9 [22.4] kg), 56 completed the trial. HU6 (vs placebo) significantly decreased weight (between-group difference, -2.86 kg; 95% CI, -4.68 to -1.04 kg; P = .003), total fat mass (between-group difference, -2.96 kg; 95% CI, -4.50 to -1.42 kg; P &lt; .001), and percentage visceral fat (between-group difference,-1.3%; 95% CI, -2.1 to -0.5%; P = .003), with no significant loss of muscle mass. There were no statistically significant changes in peak VO2, 6-minute walk distance, Kansas City Cardiomyopathy Questionnaire score, high-sensitivity C-reactive protein level, N-terminal pro-brain natriuretic peptide level, or diastolic function. Serious adverse events were noted in 5 participants (4 in the HU6 group; 1 in the placebo group), including 1 death, all judged unrelated to treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Among patients with obesity-related HFpEF, treatment with HU6 for 19 weeks led to modest but statistically significant weight loss without significant changes in peak VO2. Larger trials of longer duration are warranted to determine whether longer-term administration of HU6 can improve exercise function, quality of life, and cardiovascular outcomes in this increasingly common disorder.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05284617.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072462/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40072462</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0103>10.1001/jamacardio.2025.0103</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072462</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Gregory D Lewis</dc:creator>
<dc:creator>Barry A Borlaug</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Andrew J Sauer</dc:creator>
<dc:creator>Sheldon Litwin</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Diane K Jorkasky</dc:creator>
<dc:creator>Elizabeth A Tarka</dc:creator>
<dc:creator>Shaharyar M Khan</dc:creator>
<dc:creator>Dalane W Kitzman</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Novel Controlled Metabolic Accelerator for Obesity-Related HFpEF: The HuMAIN-HFpEF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:40072462</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0103</dc:identifier>
</item>
<item>
<title>FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072460/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this subgroup analysis of the FAME 3 randomized clinical trial, the relative benefit of CABG compared with FFR-guided PCI was similar among patients with and without diabetes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0095. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Outcomes in patients with diabetes after fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) using current-generation drug-eluting stents (DES) compared with coronary artery bypass grafting (CABG) are unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To investigate the relative treatment effect of PCI vs CABG according to diabetes status with respect to major adverse cardiac and cerebrovascular events (MACCE) at 3 years and to evaluate the impact of the SYNTAX score.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a prespecified subgroup analysis of the FAME (Fractional Flow Reserve vs Angiography for Multivessel Evaluation) 3 trial, an investigator-initiated, randomized clinical trial conducted at 48 centers worldwide. The FAME 3 trial enrolled patients with 3-vessel coronary artery disease not involving the left main undergoing coronary revascularization between August 2014 and December 2019. Data analysis was conducted in August 2023. Clinical follow-up was performed at hospital discharge and at 1 month, 6 months, 1 year, 2 years, and 3 years after randomization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Either FFR-guided PCI with current-generation DES or CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was MACCE, defined as the composite of all-cause death, myocardial infarction, stroke, or repeat revascularization at 3 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1500 total patients enrolled, mean (SD) patient age was 65.1 (8.4) years, and 265 patients (17.7%) were female. The FAME 3 trial included 428 patients with diabetes (28.5%). Patients with diabetes, especially those receiving insulin, had a higher risk of MACCE at 3 years compared with those without diabetes. Regarding relative treatment effect, the risk of MACCE was higher after FFR-guided PCI compared with CABG in both patients with diabetes (hazard ratio [HR], 1.44; 95% CI, 0.91-2.28; P = .12) and those without diabetes (HR, 1.50; 95% CI, 1.08-2.07; P = .02), with no significant interaction (P for interaction = .94). In patients with a low SYNTAX score (&lt;23), there was no significant difference in MACCE between PCI and CABG, while in patients with an intermediate to high SYNTAX score (≥23), PCI had a higher risk of MACCE than CABG, regardless of diabetes status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this subgroup analysis of the FAME 3 randomized clinical trial, the relative benefit of CABG compared with FFR-guided PCI was similar among patients with and without diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02100722.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072460/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40072460</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0095>10.1001/jamacardio.2025.0095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072460</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Kuniaki Takahashi</dc:creator>
<dc:creator>Hisao Otsuki</dc:creator>
<dc:creator>Frederik M Zimmermann</dc:creator>
<dc:creator>Victoria Y Ding</dc:creator>
<dc:creator>Thomas Engstrøm</dc:creator>
<dc:creator>Hans Gustav Hørsted Thyregod</dc:creator>
<dc:creator>Branko Beleslin</dc:creator>
<dc:creator>Svetozar Putnik</dc:creator>
<dc:creator>Luke Tapp</dc:creator>
<dc:creator>Thomas Barker</dc:creator>
<dc:creator>Simon Redwood</dc:creator>
<dc:creator>Christopher Young</dc:creator>
<dc:creator>G Jan-Willem Bech</dc:creator>
<dc:creator>Gerard J F Hoohenkerk</dc:creator>
<dc:creator>Bernard De Bruyne</dc:creator>
<dc:creator>Nico H J Pijls</dc:creator>
<dc:creator>William F Fearon</dc:creator>
<dc:creator>FAME 3 Trial Investigators</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>FFR-Guided Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting in Patients With Diabetes</dc:title>
<dc:identifier>pmid:40072460</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0095</dc:identifier>
</item>
<item>
<title>Food Insecurity and Incident Cardiovascular Disease Among Black and White US Individuals, 2000-2020</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072427/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this prospective cohort study among participants in the CARDIA study, food insecurity was associated with incident CVD even after adjustment for socioeconomic factors, suggesting that food insecurity may be an important social deprivation measure in clinical assessment of CVD risk. Whether interventions to reduce food insecurity programs can potentially alleviate CVD should be further studied.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0109. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Food insecurity is associated with prevalent cardiovascular disease (CVD), but studies have been limited to cross-sectional data.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: To study whether food insecurity is associated with incident CVD and to determine whether this association varies by sex, education, or race.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted among US adults without preexisting CVD participating in the CARDIA (Coronary Artery Risk Development in Young Adults) study from 2000 to August 31, 2020. Data analysis was conducted from December 2022 to April 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: Food insecurity, defined as endorsing limitations in household food variety and/or food quantity, assessed in the period 2000-2001.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was CVD events, consisting of fatal and nonfatal coronary heart disease, heart failure, stroke, transient ischemic attack, or peripheral arterial disease, identified annually through August 31, 2020.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 3616 total participating adults, mean (SD) age was 40.1 (3.6) years, and 2027 participants (56%) were female. Of 3616 participants, 1696 (47%) self-reported Black race and 529 participants (15%) had food insecurity at baseline. Individuals with food insecurity were more likely to self-identify as Black and report lower educational attainment. The mean (SD) follow-up period was 18.8 (3.4) years, during which 255 CVD events occurred: 57 events (11%) in food-insecure participants and 198 events (6%) in food-secure participants over the study period. After adjusting for age, sex, and field center, food insecurity was associated with incident CVD (adjusted hazard ratio [aHR], 1.90; 95% CI, 1.41-2.56). The association persisted (aHR, 1.47; 95% CI, 1.08-2.01) after further adjustment for the socioeconomic factors of education, marital status, and usual source of medical care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this prospective cohort study among participants in the CARDIA study, food insecurity was associated with incident CVD even after adjustment for socioeconomic factors, suggesting that food insecurity may be an important social deprivation measure in clinical assessment of CVD risk. Whether interventions to reduce food insecurity programs can potentially alleviate CVD should be further studied.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072427/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40072427</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0109>10.1001/jamacardio.2025.0109</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072427</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Jenny Jia</dc:creator>
<dc:creator>Mercedes R Carnethon</dc:creator>
<dc:creator>Mandy Wong</dc:creator>
<dc:creator>Cora E Lewis</dc:creator>
<dc:creator>Pamela J Schreiner</dc:creator>
<dc:creator>Namratha R Kandula</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Food Insecurity and Incident Cardiovascular Disease Among Black and White US Individuals, 2000-2020</dc:title>
<dc:identifier>pmid:40072427</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0109</dc:identifier>
</item>
<item>
<title>Exercise-Induced Dyspnea in an Older Woman With a History of Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40072426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Mar 12. doi: 10.1001/jamacardio.2025.0115. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40072426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40072426</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2025.0115>10.1001/jamacardio.2025.0115</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40072426</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Soundous M'Rabet</dc:creator>
<dc:creator>Jean-Christophe Eicher</dc:creator>
<dc:creator>Charles Guenancia</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Exercise-Induced Dyspnea in an Older Woman With a History of Coronary Artery Disease</dc:title>
<dc:identifier>pmid:40072426</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2025.0115</dc:identifier>
</item>
<item>
<title>PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40071387/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Patients with sequence variations in FH leading to defects in LDLR recycling are resistant to PCSK9 inhibitors. Genetic diagnosis and alternative drugs independent of LDLR will be needed for treatment of these patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.072336. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Low-density lipoprotein (LDL) is internalized into cells mainly through LDLR (LDL receptor)-mediated endocytosis. In an acidic endosome, LDLR is released from LDL and recycles back to the cell surface, whereas LDL is left in the endosome and degraded in the lysosome. Circulating PCSK9 (proprotein convertase subtilisin/kexin 9) binds with LDLR and is internalized into the endosome, similar to LDL. In an acidic endosome, LDLR fails to disassociate from PCSK9, and both proteins are degraded in the lysosome. PCSK9 inhibitors are widely used for treating hypercholesterolemia. However, how PCSK9 diverts LDLR to the lysosome for degradation remains elusive. Some patients are resistant to PCSK9 inhibitors, for unknown reasons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Both in vitro and in vivo approaches were used to investigate the molecular and cellular mechanisms of PCSK9-mediated LDLR degradation. LDLR containing <i>FH</i> sequence variations was expressed in <i>LDLR</i> knockout mice and knockout HuH7 cells to evaluate their response to PCSK9 and PCSK9 inhibitors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Acidic pH induces a conformational change in LDLR extracellular domain and promotes its interaction with SNX17 (sorting nexin 17) through the intracellular domain. Knocking down <i>SNX17</i> abolishes LDLR recycling and causes accelerated degradation in the lysosome. PCSK9 prevents the acidic pH-induced conformational change in LDLR and blocks its interaction with SNX17. Knocking down <i>SNX17</i> abolishes PCSK9-mediated LDLR degradation. Any <i>FH</i> sequence variations that disrupt LDLR recycling are unresponsive to PCSK9 or PCSK9 inhibitors, even though they can internalize LDL.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: PCSK9 promotes LDLR degradation by preventing SNX17-mediated LDLR recycling. Patients with sequence variations in <i>FH</i> leading to defects in LDLR recycling are resistant to PCSK9 inhibitors. Genetic diagnosis and alternative drugs independent of LDLR will be needed for treatment of these patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40071387/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40071387</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072336>10.1161/CIRCULATIONAHA.124.072336</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40071387</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>YangYang Guan</dc:creator>
<dc:creator>Xiaomin Liu</dc:creator>
<dc:creator>Zetian Yang</dc:creator>
<dc:creator>Xinyu Zhu</dc:creator>
<dc:creator>Min Liu</dc:creator>
<dc:creator>Mingkun Du</dc:creator>
<dc:creator>Xiaowei Pan</dc:creator>
<dc:creator>Yan Wang</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>PCSK9 Promotes LDLR Degradation by Preventing SNX17-Mediated LDLR Recycling</dc:title>
<dc:identifier>pmid:40071387</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072336</dc:identifier>
</item>
<item>
<title>Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40071347/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings identify a significant new stem cell signature of cardiometabolic HFpEF and support a role for myeloid maladaptive fatty acid metabolism in the promotion of systemic inflammation and cardiac diastolic dysfunction.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.070248. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment options remain limited. The HFpEF syndrome is associated with a high comorbidity burden, including high prevalence of obesity and hypertension. Although inflammation is implicated to play a key role in HFpEF pathophysiology, underlying causal mechanisms remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Comparing patient samples and animal models, we defined the innate immune response during HFpEF in situ and through flow cytometry and single-cell RNA sequencing. After identifying transcriptional and cell signatures, we implemented a high-fat diet and hypertensive model of HFpEF and tested roles for myeloid and hematopoietic stem cells during HFpEF. Contributions of macrophage metabolism were also evaluated, including through mass spectrometry and carbon labeling. Primary macrophages were studied ex vivo to gain insight into complementary cell-intrinsic mechanisms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Here we report evidence that patients with cardiometabolic HFpEF exhibit elevated peripheral blood hematopoietic stem cells. This phenotype was conserved across species in a murine mode of high-fat diet and hypertension. Hematopoietic stem cell proliferation was coupled to striking remodeling of the peripheral hematopoietic stem cell niche and expression of the macrophage adhesion molecule <i>Vcam1</i>. This could be partially inhibited by sodium-glucose cotransporter-2 inhibitors and explained by elevated fatty acid metabolism in macrophage mitochondria, which in turn remodeled the <i>Vcam1</i> promoter to enhance its expression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings identify a significant new stem cell signature of cardiometabolic HFpEF and support a role for myeloid maladaptive fatty acid metabolism in the promotion of systemic inflammation and cardiac diastolic dysfunction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40071347/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40071347</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070248>10.1161/CIRCULATIONAHA.124.070248</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40071347</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Mallory Filipp</dc:creator>
<dc:creator>Zhi-Dong Ge</dc:creator>
<dc:creator>Matthew DeBerge</dc:creator>
<dc:creator>Connor Lantz</dc:creator>
<dc:creator>Kristofor Glinton</dc:creator>
<dc:creator>Peng Gao</dc:creator>
<dc:creator>Sasha Smolgovsky</dc:creator>
<dc:creator>Jingbo Dai</dc:creator>
<dc:creator>You-Yang Zhao</dc:creator>
<dc:creator>Laurent Yvan-Charvet</dc:creator>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:creator>Samuel E Weinberg</dc:creator>
<dc:creator>Gabriele G Schiattarella</dc:creator>
<dc:creator>Joseph A Hill</dc:creator>
<dc:creator>Matthew J Feinstein</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Edward B Thorp</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Myeloid Fatty Acid Metabolism Activates Neighboring Hematopoietic Stem Cells to Promote Heart Failure With Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:40071347</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070248</dc:identifier>
</item>
<item>
<title>Endothelial Serotonin Receptor 1B Acts as a Mechanosensor to Drive Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40071330/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Taken together, these results uncover that endothelial 5-HT(1B) acts as a mechanosensor for disturbed flow and contributes to atherogenesis. Inhibition of 5-HT(1B) could be a promising therapeutic strategy for atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Mar 12. doi: 10.1161/CIRCRESAHA.124.325453. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerosis is characterized by the accumulation of fatty and fibrotic plaques, which preferentially develop at curvatures and branches along the arterial trees that are exposed to disturbed flow. However, the mechanisms by which endothelial cells sense disturbed flow are still unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The partial carotid ligation mouse model was used to investigate disturbed flow-induced atherogenesis. In vitro experiments were performed using the ibidi system to generate oscillatory shear stress and laminar shear stress. <i>ApoE</i><sup><i>-/-</i></sup> mice with endothelium-specific knockout or overexpression of 5-HT<sub>1B</sub> (serotonin receptor 1B) were used to investigate the role of endothelial 5-HT<sub>1B</sub> in atherosclerosis. RNA sequencing analysis, immunofluorescence analysis, and molecular biological techniques were used to explore the role of 5-HT<sub>1B</sub> in mechanotransduction and endothelial activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The data showed that human endothelial cells express a high level of 5-HT<sub>1B</sub>, which is a serotonin receptor subtype. Endothelial 5-HT<sub>1B</sub> is upregulated in atherosclerotic areas of both humans and rodents and is increased by disturbed flow both in vivo and in vitro. Endothelium-specific overexpression of 5-HT<sub>1B</sub> exacerbates, whereas knockout or knockdown of 5-HT<sub>1B</sub> in endothelium inhibits disturbed flow-induced endothelial inflammation and atherogenesis in both male and female <i>ApoE</i><sup><i>-/-</i></sup> mice. We reveal a previously unknown role of 5-HT<sub>1B</sub> as a mechanosensor in endothelial cells in response to mechanical stimuli. Upon activation by oscillatory shear stress, 5-HT<sub>1B</sub> recruits β-arrestin, orchestrates RhoA, and then activates mechanosensitive YAP (yes-associated protein), thereby enhancing endothelial inflammation and monocyte infiltration. Pharmacological blockade of 5-HT<sub>1B</sub> suppresses endothelial activation and atherogenesis via inhibition of YAP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Taken together, these results uncover that endothelial 5-HT<sub>1B</sub> acts as a mechanosensor for disturbed flow and contributes to atherogenesis. Inhibition of 5-HT<sub>1B</sub> could be a promising therapeutic strategy for atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40071330/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40071330</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325453>10.1161/CIRCRESAHA.124.325453</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40071330</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Minchun Jiang</dc:creator>
<dc:creator>Huanyu Ding</dc:creator>
<dc:creator>Yuhong Huang</dc:creator>
<dc:creator>Chi Wai Lau</dc:creator>
<dc:creator>Ying Guo</dc:creator>
<dc:creator>Jianfang Luo</dc:creator>
<dc:creator>Yu-Tsung Shih</dc:creator>
<dc:creator>Yin Xia</dc:creator>
<dc:creator>Xiaoqiang Yao</dc:creator>
<dc:creator>Jeng-Jiann Chiu</dc:creator>
<dc:creator>Li Wang</dc:creator>
<dc:creator>Shu Chien</dc:creator>
<dc:creator>Yu Huang</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Endothelial Serotonin Receptor 1B Acts as a Mechanosensor to Drive Atherosclerosis</dc:title>
<dc:identifier>pmid:40071330</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325453</dc:identifier>
</item>
<item>
<title>An NRF2/β3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40071326/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Moderate expression of cardiac β3AR, at levels observed in human cardiac myocardium, exerts metabolic and antioxidant effects through activation of the pentose-phosphate pathway and NRF2 pathway through S-nitrosation of Keap1, thereby preserving myocardial oxidative metabolism, function, and integrity under pathophysiological stress.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 12. doi: 10.1161/CIRCULATIONAHA.124.067876. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cardiac β3-adrenergic receptors (ARs) are upregulated in diseased hearts and mediate antithetic effects to those of β1AR and β2AR. β3AR agonists were recently shown to protect against myocardial remodeling in preclinical studies and to improve systolic function in patients with severe heart failure. However, the underlying mechanisms remain elusive.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To dissect functional, transcriptional, and metabolic effects, hearts and isolated ventricular myocytes from mice harboring a moderate, cardiac-specific expression of a human <i>ADRB3</i> transgene (β3AR-Tg) and subjected to transverse aortic constriction were assessed with echocardiography, RNA sequencing, positron emission tomography scan, metabolomics, and metabolic flux analysis. Subsequently, signaling and metabolic pathways were further investigated in vivo in β3AR-Tg and ex vivo in neonatal rat ventricular myocytes adenovirally infected to express β3AR and subjected to neurohormonal stress. These results were complemented with an analysis of single-nucleus RNA-sequencing data from human cardiac myocytes from patients with heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Compared with wild-type littermates, β3AR-Tg mice were protected from hypertrophy after transaortic constriction, and systolic function was preserved. β3AR-expressing hearts displayed enhanced myocardial glucose uptake under stress in the absence of increased lactate levels. Instead, metabolomic and metabolic flux analyses in stressed hearts revealed an increase in intermediates of the pentose-phosphate pathway in β3AR-Tg, an alternative route of glucose utilization, paralleled with increased transcript levels of NADPH-producing and rate-limiting enzymes of the pentose-phosphate pathway, without fueling the hexosamine metabolism. The ensuing increased content of NADPH and of reduced glutathione decreased myocyte oxidant stress, whereas downstream oxidative metabolism assessed by oxygen consumption was preserved with higher glucose oxidation in β3AR-Tg mice after transaortic constriction compared with wild type, together with increased mitochondrial biogenesis. Unbiased transcriptomics and pathway analysis identified NRF2 (NFE2L2) as an upstream transcription factor that was functionally verified in vivo and in β3AR-expressing cardiac myocytes, where its translocation and nuclear activity were dependent on β3AR activation of nitric oxide synthase and nitric oxide production through S-nitrosation of the NRF2-negative regulator Keap1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Moderate expression of cardiac β3AR, at levels observed in human cardiac myocardium, exerts metabolic and antioxidant effects through activation of the pentose-phosphate pathway and NRF2 pathway through S-nitrosation of Keap1, thereby preserving myocardial oxidative metabolism, function, and integrity under pathophysiological stress.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40071326/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40071326</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.067876>10.1161/CIRCULATIONAHA.124.067876</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40071326</guid>
<pubDate>Wed, 12 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Lauriane Y M Michel</dc:creator>
<dc:creator>Hrag Esfahani</dc:creator>
<dc:creator>Delphine De Mulder</dc:creator>
<dc:creator>Roxane Verdoy</dc:creator>
<dc:creator>Jérôme Ambroise</dc:creator>
<dc:creator>Véronique Roelants</dc:creator>
<dc:creator>Bertrand Bouchard</dc:creator>
<dc:creator>Nathalie Fabian</dc:creator>
<dc:creator>Jérôme Savary</dc:creator>
<dc:creator>Joseph P Dewulf</dc:creator>
<dc:creator>Thomas Doumont</dc:creator>
<dc:creator>Caroline Bouzin</dc:creator>
<dc:creator>Vincent Haufroid</dc:creator>
<dc:creator>Joost J F P Luiken</dc:creator>
<dc:creator>Miranda Nabben</dc:creator>
<dc:creator>Michael L Singleton</dc:creator>
<dc:creator>Luc Bertrand</dc:creator>
<dc:creator>Matthieu Ruiz</dc:creator>
<dc:creator>Christine Des Rosiers</dc:creator>
<dc:creator>Jean-Luc Balligand</dc:creator>
<dc:date>2025-03-12</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>An NRF2/β3-Adrenoreceptor Axis Drives a Sustained Antioxidant and Metabolic Rewiring Through the Pentose-Phosphate Pathway to Alleviate Cardiac Stress</dc:title>
<dc:identifier>pmid:40071326</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.067876</dc:identifier>
</item>
<item>
<title>Polarity-guided uneven mitotic divisions control brassinosteroid activity in proliferating plant root cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40068682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>Brassinosteroid hormones are positive regulators of plant organ growth, yet their function in proliferating tissues remains unclear. Here, through integrating single-cell RNA sequencing with long-term live-cell imaging of the Arabidopsis root, we reveal that brassinosteroid activity fluctuates throughout the cell cycle, decreasing during mitotic divisions and increasing during the G1 phase. The post-mitotic recovery of brassinosteroid activity is driven by the intrinsic polarity of the mother...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 6:S0092-8674(25)00196-5. doi: 10.1016/j.cell.2025.02.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Brassinosteroid hormones are positive regulators of plant organ growth, yet their function in proliferating tissues remains unclear. Here, through integrating single-cell RNA sequencing with long-term live-cell imaging of the Arabidopsis root, we reveal that brassinosteroid activity fluctuates throughout the cell cycle, decreasing during mitotic divisions and increasing during the G1 phase. The post-mitotic recovery of brassinosteroid activity is driven by the intrinsic polarity of the mother cell, resulting in one daughter cell with enhanced brassinosteroid signaling, while the other supports brassinosteroid biosynthesis. The coexistence of these distinct daughter cell states during the G1 phase circumvents a negative feedback loop to facilitate brassinosteroid production while signaling increases. Our findings uncover polarity-guided, uneven mitotic divisions in the meristem, which control brassinosteroid hormone activity to ensure optimal root growth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40068682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40068682</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.011>10.1016/j.cell.2025.02.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40068682</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Nemanja Vukašinović</dc:creator>
<dc:creator>Che-Wei Hsu</dc:creator>
<dc:creator>Marco Marconi</dc:creator>
<dc:creator>Shaopeng Li</dc:creator>
<dc:creator>Christopher Zachary</dc:creator>
<dc:creator>Rachel Shahan</dc:creator>
<dc:creator>Pablo Szekley</dc:creator>
<dc:creator>Ziv Aardening</dc:creator>
<dc:creator>Isabelle Vanhoutte</dc:creator>
<dc:creator>Qian Ma</dc:creator>
<dc:creator>Lucrezia Pinto</dc:creator>
<dc:creator>Pavel Krupař</dc:creator>
<dc:creator>Nathan German</dc:creator>
<dc:creator>Jingyuan Zhang</dc:creator>
<dc:creator>Claire Simon-Vezo</dc:creator>
<dc:creator>Jessica Perez-Sancho</dc:creator>
<dc:creator>Pepe Cana Quijada</dc:creator>
<dc:creator>Qianzi Zhou</dc:creator>
<dc:creator>Laura R Lee</dc:creator>
<dc:creator>Jianghua Cai</dc:creator>
<dc:creator>Emmanuelle M Bayer</dc:creator>
<dc:creator>Matyáš Fendrych</dc:creator>
<dc:creator>Elisabeth Truernit</dc:creator>
<dc:creator>Yu Zhou</dc:creator>
<dc:creator>Sigal Savaldi-Goldstein</dc:creator>
<dc:creator>Krzysztof Wabnik</dc:creator>
<dc:creator>Trevor M Nolan</dc:creator>
<dc:creator>Eugenia Russinova</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Polarity-guided uneven mitotic divisions control brassinosteroid activity in proliferating plant root cells</dc:title>
<dc:identifier>pmid:40068682</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.011</dc:identifier>
</item>
<item>
<title>Genome-scale resources in the infant gut symbiont Bifidobacterium breve reveal genetic determinants of colonization and host-microbe interactions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40068681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>Bifidobacteria represent a dominant constituent of human gut microbiomes during infancy, influencing nutrition, immune development, and resistance to infection. Despite interest in bifidobacteria as a live biotic therapy, our understanding of colonization, host-microbe interactions, and the health-promoting effects of bifidobacteria is limited. To address these major knowledge gaps, we used a large-scale genetic approach to create a mutant fitness compendium in Bifidobacterium breve. First, we...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 7:S0092-8674(25)00195-3. doi: 10.1016/j.cell.2025.02.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Bifidobacteria represent a dominant constituent of human gut microbiomes during infancy, influencing nutrition, immune development, and resistance to infection. Despite interest in bifidobacteria as a live biotic therapy, our understanding of colonization, host-microbe interactions, and the health-promoting effects of bifidobacteria is limited. To address these major knowledge gaps, we used a large-scale genetic approach to create a mutant fitness compendium in Bifidobacterium breve. First, we generated a high-density randomly barcoded transposon insertion pool and used it to determine fitness requirements during colonization of germ-free mice and chickens with multiple diets and in response to hundreds of in vitro perturbations. Second, to enable mechanistic investigation, we constructed an ordered collection of insertion strains covering 1,462 genes. We leveraged these tools to reveal community- and diet-specific requirements for colonization and to connect the production of immunomodulatory molecules to growth benefits. These resources will catalyze future investigations of this important beneficial microbe.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40068681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40068681</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.010>10.1016/j.cell.2025.02.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40068681</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Anthony L Shiver</dc:creator>
<dc:creator>Jiawei Sun</dc:creator>
<dc:creator>Rebecca Culver</dc:creator>
<dc:creator>Arvie Violette</dc:creator>
<dc:creator>Char Wynter</dc:creator>
<dc:creator>Marta Nieckarz</dc:creator>
<dc:creator>Samara Paula Mattiello</dc:creator>
<dc:creator>Prabhjot Kaur Sekhon</dc:creator>
<dc:creator>Francesca Bottacini</dc:creator>
<dc:creator>Lisa Friess</dc:creator>
<dc:creator>Hans K Carlson</dc:creator>
<dc:creator>Daniel P G H Wong</dc:creator>
<dc:creator>Steven Higginbottom</dc:creator>
<dc:creator>Meredith Weglarz</dc:creator>
<dc:creator>Weigao Wang</dc:creator>
<dc:creator>Benjamin D Knapp</dc:creator>
<dc:creator>Emma Guiberson</dc:creator>
<dc:creator>Juan Sanchez</dc:creator>
<dc:creator>Po-Hsun Huang</dc:creator>
<dc:creator>Paulo A Garcia</dc:creator>
<dc:creator>Cullen R Buie</dc:creator>
<dc:creator>Benjamin H Good</dc:creator>
<dc:creator>Brian DeFelice</dc:creator>
<dc:creator>Felipe Cava</dc:creator>
<dc:creator>Joy Scaria</dc:creator>
<dc:creator>Justin L Sonnenburg</dc:creator>
<dc:creator>Douwe Van Sinderen</dc:creator>
<dc:creator>Adam M Deutschbauer</dc:creator>
<dc:creator>Kerwyn Casey Huang</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Genome-scale resources in the infant gut symbiont Bifidobacterium breve reveal genetic determinants of colonization and host-microbe interactions</dc:title>
<dc:identifier>pmid:40068681</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.010</dc:identifier>
</item>
<item>
<title>Engineering mtDNA deletions by reconstituting end joining in human mitochondria</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40068680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>Recent breakthroughs in the genetic manipulation of mitochondrial DNA (mtDNA) have enabled precise base substitutions and the efficient elimination of genomes carrying pathogenic mutations. However, reconstituting mtDNA deletions linked to mitochondrial myopathies remains challenging. Here, we engineered mtDNA deletions in human cells by co-expressing end-joining (EJ) machinery and targeted endonucleases. Using mitochondrial EJ (mito-EJ) and mito-ScaI, we generated a panel of clonal cell lines...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Mar 5:S0092-8674(25)00194-1. doi: 10.1016/j.cell.2025.02.009. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Recent breakthroughs in the genetic manipulation of mitochondrial DNA (mtDNA) have enabled precise base substitutions and the efficient elimination of genomes carrying pathogenic mutations. However, reconstituting mtDNA deletions linked to mitochondrial myopathies remains challenging. Here, we engineered mtDNA deletions in human cells by co-expressing end-joining (EJ) machinery and targeted endonucleases. Using mitochondrial EJ (mito-EJ) and mito-ScaI, we generated a panel of clonal cell lines harboring a ∼3.5 kb mtDNA deletion across the full spectrum of heteroplasmy. Investigating these cells revealed a critical threshold of ∼75% deleted genomes, beyond which oxidative phosphorylation (OXPHOS) protein depletion, metabolic disruption, and impaired growth in galactose-containing media were observed. Single-cell multiomic profiling identified two distinct nuclear gene deregulation responses: one triggered at the deletion threshold and another progressively responding to heteroplasmy. Ultimately, we show that our method enables the modeling of disease-associated mtDNA deletions across cell types and could inform the development of targeted therapies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40068680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40068680</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.02.009>10.1016/j.cell.2025.02.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40068680</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Yi Fu</dc:creator>
<dc:creator>Max Land</dc:creator>
<dc:creator>Tamar Kavlashvili</dc:creator>
<dc:creator>Ruobing Cui</dc:creator>
<dc:creator>Minsoo Kim</dc:creator>
<dc:creator>Emily DeBitetto</dc:creator>
<dc:creator>Toby Lieber</dc:creator>
<dc:creator>Keun Woo Ryu</dc:creator>
<dc:creator>Elim Choi</dc:creator>
<dc:creator>Ignas Masilionis</dc:creator>
<dc:creator>Rahul Saha</dc:creator>
<dc:creator>Meril Takizawa</dc:creator>
<dc:creator>Daphne Baker</dc:creator>
<dc:creator>Marco Tigano</dc:creator>
<dc:creator>Caleb A Lareau</dc:creator>
<dc:creator>Ed Reznik</dc:creator>
<dc:creator>Roshan Sharma</dc:creator>
<dc:creator>Ronan Chaligne</dc:creator>
<dc:creator>Craig B Thompson</dc:creator>
<dc:creator>Dana Pe'er</dc:creator>
<dc:creator>Agnel Sfeir</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineering mtDNA deletions by reconstituting end joining in human mitochondria</dc:title>
<dc:identifier>pmid:40068680</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.02.009</dc:identifier>
</item>
<item>
<title>Remote ischaemic pre-conditioning, kidney injury, and outcomes after coronary angiography and intervention: a randomized trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40067773/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Among at-risk patients undergoing CAG or PCI, the incidence of CA-AKI was lower in patients receiving delayed compared with sham RIPC. These results should be confirmed in larger trials to investigate whether reductions in CA-AKI with delayed RIPC lead to important clinical benefits.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 11:ehaf135. doi: 10.1093/eurheartj/ehaf135. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Remote ischaemic pre-conditioning (RIPC) delivered shortly prior to an angiographic procedure may reduce contrast-associated acute kidney injury (CA-AKI). Whether a longer interval between RIPC and contrast administration also reduces CA-AKI and post-procedural complications after coronary angiography (CAG) or percutaneous coronary intervention (PCI) is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a multicentre, randomized trial of patients at risk of CA-AKI undergoing elective CAG or PCI comparing delayed RIPC (four cycles of 5 min inflations on one upper arm 24 h before the procedure) with sham RIPC. The primary endpoint was the incidence of AKI, defined according to the Kidney Disease Improving Global Outcomes criteria. Secondary endpoints included renal replacement therapy during hospitalization, changes in urinary biomarkers of kidney injury, and occurrence of non-fatal myocardial infarction, stroke, re-hospitalization, and all-cause mortality by day 90.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Altogether, 501 patients (age, 74 [66, 78] years) were randomly assigned to delayed (n = 250) or sham (n = 251) RIPC, of which 467 (93.2%) completed outcome assessments at day 90. The incidence of CA-AKI was 7.6% with sham and 3.2% with delayed RIPC (odds ratio 0.4, 95% confidence interval 0.17-0.94; P = .03). The trial was not adequately powered to show effects on secondary outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Among at-risk patients undergoing CAG or PCI, the incidence of CA-AKI was lower in patients receiving delayed compared with sham RIPC. These results should be confirmed in larger trials to investigate whether reductions in CA-AKI with delayed RIPC lead to important clinical benefits.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40067773/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40067773</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf135>10.1093/eurheartj/ehaf135</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40067773</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Ping Jia</dc:creator>
<dc:creator>Gang Zhao</dc:creator>
<dc:creator>Yuli Huang</dc:creator>
<dc:creator>Zhouping Zou</dc:creator>
<dc:creator>Qi Zeng</dc:creator>
<dc:creator>Weize Chen</dc:creator>
<dc:creator>Ting Ren</dc:creator>
<dc:creator>Yang Li</dc:creator>
<dc:creator>Xiaoyan Wang</dc:creator>
<dc:creator>Tingting Kang</dc:creator>
<dc:creator>Zhihe Liu</dc:creator>
<dc:creator>Mengqing Ma</dc:creator>
<dc:creator>Jiwei Yu</dc:creator>
<dc:creator>Qiong Wu</dc:creator>
<dc:creator>Bing Deng</dc:creator>
<dc:creator>Xiaoxiang Yan</dc:creator>
<dc:creator>Xin Wan</dc:creator>
<dc:creator>Xin Chen</dc:creator>
<dc:creator>Changchun Cao</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:creator>Xiaoqiang Ding</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Remote ischaemic pre-conditioning, kidney injury, and outcomes after coronary angiography and intervention: a randomized trial</dc:title>
<dc:identifier>pmid:40067773</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf135</dc:identifier>
</item>
<item>
<title>Epicardial adipose tissue and malignant ventricular arrhythmias in phospholamban p.(Arg14del) variant carriers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40067768/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 11:ehaf118. doi: 10.1093/eurheartj/ehaf118. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40067768/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40067768</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf118>10.1093/eurheartj/ehaf118</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40067768</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Belend Mahmoud</dc:creator>
<dc:creator>Moniek G P J Cox</dc:creator>
<dc:creator>Remco de Brouwer</dc:creator>
<dc:creator>Myrthe Y C van der Heide</dc:creator>
<dc:creator>Thomas M Gorter</dc:creator>
<dc:creator>Laura M G Meems</dc:creator>
<dc:creator>Arthur A M Wilde</dc:creator>
<dc:creator>Dirk J van Veldhuisen</dc:creator>
<dc:creator>Rudolf A de Boer</dc:creator>
<dc:creator>B Daan Westenbrink</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Epicardial adipose tissue and malignant ventricular arrhythmias in phospholamban p.(Arg14del) variant carriers</dc:title>
<dc:identifier>pmid:40067768</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf118</dc:identifier>
</item>
<item>
<title>Cardiovascular safety of assisted reproductive technologies: what have we learned and what remains unknown?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40067679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 11:ehaf108. doi: 10.1093/eurheartj/ehaf108. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40067679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40067679</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf108>10.1093/eurheartj/ehaf108</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40067679</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Zhenjiao Liang</dc:creator>
<dc:creator>Dongna Wang</dc:creator>
<dc:creator>Xiaoping Wang</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular safety of assisted reproductive technologies: what have we learned and what remains unknown?</dc:title>
<dc:identifier>pmid:40067679</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf108</dc:identifier>
</item>
<item>
<title>Cardiovascular safety of assisted reproductive technologies: what is next?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40067673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 11:ehaf088. doi: 10.1093/eurheartj/ehaf088. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40067673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40067673</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf088>10.1093/eurheartj/ehaf088</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40067673</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Carlo Andrea Pivato</dc:creator>
<dc:creator>Giulio Stefanini</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiovascular safety of assisted reproductive technologies: what is next?</dc:title>
<dc:identifier>pmid:40067673</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf088</dc:identifier>
</item>
<item>
<title>Oral health benefits and safety of xylitol and potential cardiovascular risk: questioning the validity of the model of Witkowski et al</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40067657/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 11:ehaf058. doi: 10.1093/eurheartj/ehaf058. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40067657/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40067657</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf058>10.1093/eurheartj/ehaf058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40067657</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Gregory C Valentine</dc:creator>
<dc:creator>Eva Söderling</dc:creator>
<dc:creator>Peter Milgrom</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Oral health benefits and safety of xylitol and potential cardiovascular risk: questioning the validity of the model of Witkowski et al</dc:title>
<dc:identifier>pmid:40067657</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf058</dc:identifier>
</item>
<item>
<title>Xylitol and cardiovascular risks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40067656/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Mar 11:ehaf059. doi: 10.1093/eurheartj/ehaf059. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40067656/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40067656</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf059>10.1093/eurheartj/ehaf059</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40067656</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Marco Witkowski</dc:creator>
<dc:creator>Stanley L Hazen</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Xylitol and cardiovascular risks</dc:title>
<dc:identifier>pmid:40067656</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf059</dc:identifier>
</item>
<item>
<title>Highlights From the Circulation Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40067098/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Oct 29;150(18):1469-1474. doi: 10.1161/CIRCULATIONAHA.124.072348. Epub 2024 Oct 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40067098/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40067098</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072348>10.1161/CIRCULATIONAHA.124.072348</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40067098</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:date>2025-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the Circulation Family of Journals</dc:title>
<dc:identifier>pmid:40067098</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072348</dc:identifier>
</item>
<item>
<title>Sex Differences in Peripheral Vascular Disease: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40066579/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>Sex differences in the risk factors, diagnosis, treatment, and outcomes of patients with cardiovascular disease have been well described; however, the bulk of the literature has focused on heart disease in women. Data on sex differences in peripheral vascular disease are ill defined, and there is a need to report and understand those sex-related differences to mitigate adverse outcomes related to those disparities. Although peripheral vascular disease is a highly diverse group of disorders...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 11. doi: 10.1161/CIR.0000000000001310. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Sex differences in the risk factors, diagnosis, treatment, and outcomes of patients with cardiovascular disease have been well described; however, the bulk of the literature has focused on heart disease in women. Data on sex differences in peripheral vascular disease are ill defined, and there is a need to report and understand those sex-related differences to mitigate adverse outcomes related to those disparities. Although peripheral vascular disease is a highly diverse group of disorders affecting the arteries, veins, and lymphatics, this scientific statement focuses on disorders affecting the peripheral arteries to include the aorta and its branch vessels. The purpose of this scientific statement is to report the current status of sex-based differences and disparities in peripheral vascular disease and to provide research priorities to achieve health equity for women with peripheral vascular disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40066579/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40066579</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001310>10.1161/CIR.0000000000001310</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40066579</guid>
<pubDate>Tue, 11 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Esther S H Kim</dc:creator>
<dc:creator>Shipra Arya</dc:creator>
<dc:creator>Yolanda Bryce</dc:creator>
<dc:creator>Heather L Gornik</dc:creator>
<dc:creator>Chandler A Long</dc:creator>
<dc:creator>Mary M McDermott</dc:creator>
<dc:creator>Amy West Pollak</dc:creator>
<dc:creator>Vincent Lopez Rowe</dc:creator>
<dc:creator>Alexander E Sullivan</dc:creator>
<dc:creator>Mary O Whipple</dc:creator>
<dc:creator>American Heart Association Council on Peripheral Vascular Disease; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Quality of Care and Outcomes Research; and Stroke Council</dc:creator>
<dc:date>2025-03-11</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sex Differences in Peripheral Vascular Disease: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:40066579</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001310</dc:identifier>
</item>
<item>
<title>Correction to: Prevalence of Coronary Atherosclerosis in Female Masters Endurance Athletes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40063726/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 11;151(10):e709. doi: 10.1161/CIR.0000000000001320. Epub 2025 Mar 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40063726/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40063726</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001320>10.1161/CIR.0000000000001320</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40063726</guid>
<pubDate>Mon, 10 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Efstathios Papatheodorou</dc:creator>
<dc:creator>Vincent L Aengevaeren</dc:creator>
<dc:creator>Thijs M H Eijsvogels</dc:creator>
<dc:creator>Khaled AlFakih</dc:creator>
<dc:creator>Rebecca Kathryn Hughes</dc:creator>
<dc:creator>Ahmed Merghani</dc:creator>
<dc:creator>Christine K Kissel</dc:creator>
<dc:creator>Saad Fyyaz</dc:creator>
<dc:creator>Athanasios Bakalakos</dc:creator>
<dc:creator>Mathew G Wilson</dc:creator>
<dc:creator>Damini Dey</dc:creator>
<dc:creator>Gherardo Finocchiaro</dc:creator>
<dc:creator>Gemma Parry-Williams</dc:creator>
<dc:creator>Camilla Torlasco</dc:creator>
<dc:creator>Michael Papadakis</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Sanjay Sharma</dc:creator>
<dc:date>2025-03-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Prevalence of Coronary Atherosclerosis in Female Masters Endurance Athletes</dc:title>
<dc:identifier>pmid:40063726</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001320</dc:identifier>
</item>
<item>
<title>Correction to: Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide to Oral and Intravenous Formulations</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/40063725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250312225205&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Mar 11;151(10):e708. doi: 10.1161/CIR.0000000000001317. Epub 2025 Mar 10.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/40063725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250312225205&v=2.18.0.post9+e462414">40063725</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001317>10.1161/CIR.0000000000001317</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:40063725</guid>
<pubDate>Mon, 10 Mar 2025 06:00:00 -0400</pubDate>
<dc:creator>Andrew P Ambrosy</dc:creator>
<dc:creator>Daniel Bensimhon</dc:creator>
<dc:creator>Galina Bernstein</dc:creator>
<dc:creator>Brian Kolski</dc:creator>
<dc:creator>Joel Neutel</dc:creator>
<dc:creator>Anuradha Lala</dc:creator>
<dc:creator>Navin K Kapur</dc:creator>
<dc:creator>Benjamin Esque</dc:creator>
<dc:creator>Eric Adler</dc:creator>
<dc:date>2025-03-10</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Correction to: Randomized Study Comparing a Novel Intranasal Formulation of Bumetanide to Oral and Intravenous Formulations</dc:title>
<dc:identifier>pmid:40063725</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001317</dc:identifier>
</item>





























</channel>
</rss>